Meridian Bioscience, Inc (Meridian Bioscience) has signed two new international distribution agreements. In Australia, Meridian has signed with Immuno Pty, Ltd, based in Sydney. For Argentina, Meridian has signed with Scott Pharma. The decision is consistent with Meridian's stated commitment to expand its non-US businesses.
Todd Motto, vice president of sales and marketing, Meridian Bioscience commented, “Following a thorough evaluation of the Australian and Argentinean markets, it is clear that Immuno Pty and Scott Pharma business models align very well with ours. We feel strongly that these are the best partners to ensure expertise in sales, technical support and outstanding customer service. We’re confident that this combination of market expertise and Meridian’s superior quality products will be very successful.”
John A. Kraeutler, chief executive officer, Meridian Bioscience commented, “The effective global distribution of our rapid tests for infectious disease is one of Meridian’s key strategies. This is a visible demonstration of our previously communicated objective to improve and expand distribution outside the U.S. By working closely with ideal partners, such as Immuno Pty and Scott Pharma, we can provide opportunities for long-term growth for Meridian and its distributors around the world.”
Martin Armstrong, Immuno Pty’s chief executive officer, stated, “Over the past 25 years we have worked hard to provide the community with products and services that will increase the standard of health and health outcomes. Meridian’s focus is the same as ours, combining high level of technical service and expertise with innovative products. Immuno is very excited to add Meridian Bioscience to our offerings and look forward to serving all of the needs in the microbiology and infectious disease testing area of the laboratory.”
Adrian Uccello, Scott Pharma’s director (from Cassara Holding Group), stated, “We are excited to bring Meridian’s product into our portfolio given the strong alignment of their unique products to the Argentina market. We are particularly excited about the opportunities for E. coli detection with their innovative ImmunoCard STAT!(R) EHEC product.”